| Primary |
| Psoriasis |
52.2% |
| Product Used For Unknown Indication |
13.8% |
| Drug Use For Unknown Indication |
12.2% |
| Pustular Psoriasis |
2.6% |
| Pityriasis Rubra Pilaris |
1.9% |
| Squamous Cell Carcinoma |
1.9% |
| Ichthyosis |
1.7% |
| Skin Cancer |
1.6% |
| Keratosis Follicular |
1.4% |
| Neuropathy Peripheral |
1.4% |
| Tooth Fracture |
1.4% |
| Lichen Planus |
1.2% |
| Prophylaxis |
1.0% |
| Acne |
0.9% |
| Contraception |
0.9% |
| Ill-defined Disorder |
0.9% |
| Skin Plaque |
0.9% |
| Depression |
0.7% |
| Dermatosis |
0.7% |
| Immunosuppression |
0.7% |
|
| Pregnancy |
16.5% |
| Skin Exfoliation |
15.5% |
| Alopecia |
7.7% |
| Drug Ineffective |
7.2% |
| Psoriasis |
5.2% |
| Transmission Of Drug Via Semen |
5.2% |
| Drug Exposure During Pregnancy |
4.1% |
| Treatment Noncompliance |
4.1% |
| Vision Blurred |
3.6% |
| Weight Increased |
3.6% |
| Off Label Use |
3.1% |
| Therapeutic Response Unexpected |
3.1% |
| Wound Secretion |
3.1% |
| Grand Mal Convulsion |
2.6% |
| Headache |
2.6% |
| Maternal Exposure Before Pregnancy |
2.6% |
| Oedema Peripheral |
2.6% |
| Pulmonary Embolism |
2.6% |
| Visual Acuity Reduced |
2.6% |
| Weight Decreased |
2.6% |
|
| Secondary |
| Psoriasis |
26.0% |
| Drug Use For Unknown Indication |
23.1% |
| Product Used For Unknown Indication |
18.5% |
| Antiplatelet Therapy |
5.3% |
| Depression |
4.3% |
| Erythrodermic Psoriasis |
3.6% |
| Asthma |
2.8% |
| Dyslipidaemia |
2.5% |
| Psoriatic Arthropathy |
2.5% |
| Gout |
1.8% |
| Hypertension |
1.8% |
| Keratosis Follicular |
1.4% |
| Ichthyosis |
1.1% |
| Type 1 Diabetes Mellitus |
1.1% |
| Acne |
0.7% |
| Antidepressant Therapy |
0.7% |
| Anxiety |
0.7% |
| Dermatosis |
0.7% |
| Insomnia |
0.7% |
| Pustular Psoriasis |
0.7% |
|
| Weight Decreased |
17.6% |
| Hypoglycaemic Seizure |
7.8% |
| Skin Inflammation |
7.8% |
| Gamma-glutamyltransferase Increased |
5.9% |
| Hepatic Enzyme Increased |
5.9% |
| Ventricular Tachycardia |
5.9% |
| Drug Ineffective |
3.9% |
| Drug-induced Liver Injury |
3.9% |
| Microcytic Anaemia |
3.9% |
| Onychoclasis |
3.9% |
| Psoriasis |
3.9% |
| Pustular Psoriasis |
3.9% |
| Rash |
3.9% |
| Speech Disorder |
3.9% |
| Tachycardia |
3.9% |
| Thrombocytopenia |
3.9% |
| Viral Infection |
3.9% |
| Alopecia |
2.0% |
| Angina Unstable |
2.0% |
| Aspartate Aminotransferase Increased |
2.0% |
|
| Concomitant |
| Psoriasis |
38.4% |
| Product Used For Unknown Indication |
23.3% |
| Drug Use For Unknown Indication |
6.8% |
| Psoriatic Arthropathy |
6.6% |
| Hypertension |
4.9% |
| Pain |
4.0% |
| Diabetes Mellitus |
3.2% |
| Blood Cholesterol Increased |
1.7% |
| Insomnia |
1.4% |
| Prophylaxis |
1.4% |
| Depression |
1.0% |
| Sleep Disorder |
0.9% |
| Type 2 Diabetes Mellitus |
0.9% |
| Anxiety |
0.9% |
| Inflammation |
0.9% |
| Asthma |
0.8% |
| Cardiac Disorder |
0.8% |
| Diuretic Therapy |
0.8% |
| Electrolyte Substitution Therapy |
0.8% |
| Hyperlipidaemia |
0.8% |
|
| Psoriasis |
25.4% |
| Injection Site Pain |
10.1% |
| Weight Decreased |
7.1% |
| Vomiting |
5.9% |
| Acute Myocardial Infarction |
5.3% |
| Drug Ineffective |
4.1% |
| Muscular Weakness |
3.6% |
| Myocardial Infarction |
3.6% |
| Retinoic Acid Syndrome |
3.6% |
| Therapeutic Response Decreased |
3.6% |
| Injection Site Bruising |
3.0% |
| Migraine |
3.0% |
| Osteonecrosis |
3.0% |
| Pruritus |
3.0% |
| Skin Exfoliation |
3.0% |
| Staphylococcal Sepsis |
3.0% |
| Urinary Tract Infection |
3.0% |
| Bladder Cancer |
2.4% |
| Injection Site Irritation |
2.4% |
| Oedema Peripheral |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
83.3% |
| Psoriasis |
16.7% |
|
| Gamma-glutamyltransferase Increased |
100.0% |
|
